Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention

The Lancet

Volumn 382, Issue 9889, 2013, Pages 339-352

  Gansevoort, Ron T ^a   Correa Rotter, Ricardo ^b   Hemmelgarn, Brenda R ^c   Jafar, Tazeen H ^d   Heerspink, Hiddo J Lambers ^a   Mann, Johannes F ^e,f   Matsushita, Kunihiro ^g   Wen, Chi Pang ^h,i  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b National Institute for Medica Sciences and Nutrition Salvador Zubiran   (Mexico)

^c UNIVERSITY OF CALGARY   (Canada)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

^e Munich General Hospital   (Germany)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^h CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁱ NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMINURIA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; HUMAN; KIDNEY DYSFUNCTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 84880922135     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60595-4     Document Type: Review

References (115)

1. R Bright Cases and observations illustrative of renal disease accompanied with the secretion of albuminous urine Guy's Hospital Trans 1 1836 338 379
2. J Harlos, A Heidland Hypertension as cause and consequence of renal disease in the 19th century Am J Nephrol 14 1994 436 442
3. K-U Eckardt, J Coresh, O Devuyst et al. Evolving importance of kidney disease: from subspecialty to global health burden Lancet 2013 published online May 27. http://dx.doi.org/10.1016/S0140-6736(13)60439-0
4. Kidney Disease: Improving Global Outcomes (KDIGO) Work Group KDIGO clinical practice guideline for evaluation and management of chronic kidney disease Kidney Int Suppl 3 2013 1 163
5. K Matsushita, M van der Velde, BC Astor for the CKD Prognosis Consortium Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis Lancet 375 2010 2073 2081
6. M Van der Velde, K Matsushita, J Coresh for the Chronic Kidney Disease Prognosis Consortium Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts Kidney Int 79 2011 1341 1352
7. A Kottgen, SD Russell, LR Loehr et al. Reduced kidney function as a risk factor for incident heart failure: the Atherosclerosis Risk In Communities (ARIC) study J Am Soc Nephrol 18 2007 1307 1315
8. JL Abramson, CT Jurkovitz, V Vaccarino, WS Weintraub, W McClellan Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC study Kidney Int 64 2003 610 615
9. K Wattanakit, AR Folsom, E Selvin, J Coresh, AT Hirsch, BD Weatherley Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk In Communities (ARIC) study J Am Soc Nephrol 18 2007 629 636
10. BC Astor, J Coresh, G Heiss, D Pettitt, MJ Sarnak Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk In Communities (ARIC) study Am Heart J 151 2006 492 500
11. A Alonso, FL Lopez, K Matsushita et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk In Communities (ARIC) study Circulation 123 2011 2946 2953
12. MI Aguilar, ES O'Meara, S Seliger et al. Albuminuria and the risk of incident stroke and stroke types in older adults Neurology 75 2010 1313 1343
13. SI Hallan, K Matsushita, Y Sang for the Chronic Kidney Disease Prognosis Consortium Age and association of kidney measures with mortality and end-stage renal disease JAMA 308 2012 2349 2360
14. D Nitsch, M Grams, Y Sang for the Chronic Kidney Disease Prognosis Consortium Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis BMJ 346 2013 f324
15. AS Go, GM Chertow, D Fan, CE McCulloch, CY Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296 1305
16. SI Hallan, BC Astor, S Romundstad, K Aasarod, K Kvenild, J Coresh Association of kidney function and albuminuria with cardiovascular mortality in older versus younger individuals; the HUNT II study Arch Intern Med 167 2007 2490 2496
17. TYD Cheng, SF Wen, BC Astor, XG Tao, JM Samet, CP Wen Mortality risks for all causes and cardiovascular diseases and reduced GFR in a middle-aged working population in Taiwan Am J Kidney Dis 52 2008 1051 1060
18. CS Fox, K Matsushita, M Woodward for the Chronic Kidney Disease Prognosis Consortium Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: A meta-analysis of 1 024 977 individuals Lancet 380 2012 1662 1673
19. Mahmoodi BK, Matsushita K, Woodward M, et al, for the Chronic Kidney Disease Prognosis Consortium, Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 380: 1649-61.
20. M Tonelli, P Muntner, A Lloyd for the Alberta Kidney Disease Network Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study Lancet 380 2012 807 814
21. J Perk, G De Backer, H Gohlke for the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice European Association for Cardiovascular Prevention and Rehabilitation European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) Atherosclerosis 223 2012 1 68
22. CP Wen, TYD Cheng, MK Tsai All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan Lancet 371 2008 2173 2182
23. BR Hemmelgarn, F Clement, BJ Manns et al. Overview of the Alberta Kidney Disease Network BMC Nephrol 10 2009 30
24. TC Turin, M Tonelli, BJ Manns, P Ravani, SB Ahmed, BR Hemmelgarn Chronic kidney disease and life expectancy Nephrol Dial Transplant 27 2012 3182 3186
25. TC Turin, M Tonelli, BJ Manns et al. Proteinuria and life expectancy Am J Kidney Dis 61 2013 646 668
26. OH Franco, EW Steyerberg, FB Hu, J Mackenbach, W Nusselder Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease Arch Intern Med 167 2007 1145 1151
27. L Loukine, C Waters, BC Choi, J Ellison Health-adjusted life expectancy among Canadian adults with and without hypertension Cardiol Res Pract 2011 2011 612968
28. OH Franco, A Peeters, L Bonneux, C De Laet Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women: life course analysis Hypertension 46 2005 280 286
29. RT Gansevoort, K Matsushita, M van der Velde for the Chronic Kidney Disease Prognosis Consortium Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts Kidney Int 80 2011 93 104
30. PE De Jong, M van der Velde, RT Gansevoort, C Zoccali Screening for chronic kidney disease: where does Europe go? Clin J Am Soc Nephrol 3 2008 616 623
31. DK Packham, TP Alves, JP Dwyer et al. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC database Am J Kidney Dis 59 2012 75 83
32. EL Schiffrin, ML Lipman, JFE Mann Chronic kidney disease: effects on the cardiovascular system Circulation 116 2007 85 97
33. Y Kokubo, S Nakamura, T Okamura et al. Relationship between blood pressure category and incidence of stroke and myocardial infarction in an urban Japanese population with and without chronic kidney disease: the SUITA study Stroke 40 2009 2674 2679
34. A Upadhyay, A Earley, SM Haynes, K Uhlig Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier Ann Intern Med 154 2011 541 548
35. A Levin, J Singer, CR Thompson, H Ross, M Lewis Prevalent LVH in the predialysis population: Identifying opportunities for intervention Am J Kidney Dis 27 1996 347 354
36. A Levin, RN Foley Cardiovascular disease in chronic renal insufficiency Am J Kidney Dis 36 suppl 3 2000 S24 S30
37. B Pannier, AP Guèrin, SJ Marchais, ME Safar, GM London Stiffness of capacitive and conduit arteries prognostic significance for end-stage renal disease patients Hypertension 45 2005 592 596
38. C Drechsler, V Krane, K Winkler, VW Dekker, C Wanner Changes in adiponectin and risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients Kidney Int 56 2009 567 575
39. D Green, PR Roberts, DI New, PA Kalra Sudden cardiac death in hemodialysis patients: an in-depth review Am J Kidney Dis 57 2011 921 929
40. V Krane, C Wanner Statins, inflammation and kidney disease Nat Rev Nephrol 6 2011 1573 1579
41. GL Bakris Lipid disorders in uremia and dialysis Contrib Nephrol 178 2012 100 105
42. P Ochodnicky, RH Henning, RP van Dokkum, D de Zeeuw Microalbuminuria and endothelial dysfunction: emerging targets for primary prevention of end-organ damage J Cardiovasc Pharmacol 47 2006 S151 S162
43. JT Kielstein, C Zoccali Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? Am J Kidney Dis 46 2005 186 202
44. C Zoccali, F Mallamaci, R Maas for the CREED Investigators Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients Kidney Int 62 2002 339 345
45. M Ketteler, G Schlieper, J Floege Calcification and cardiovascular health: new insights into an old phenomenon Hypertension 47 2006 1027 1034
46. LD Quarles Endocrine functions of bone in mineral metabolism regulation J Clin Invest 118 2008 3820 3828
47. ML Melamed, RI Thadhani Vitamin D therapy in chronic kidney disease and end stage renal disease Clin J Am Soc Nephrol 7 2012 358 365
48. C Ronco, M Haapio, AA House, N Anavekar, R Bellomo Cardiorenal syndrome J Am Coll Cardiol 52 2008 1527 1539
49. AJ Bleyer, LR Shemanski, GL Burke, KJ Hansen, RG Appel Tobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population Kidney Int 57 2000 2072 2079
50. JE Heeg, PE de Jong, GK van der Hem, D de Zeeuw Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril Kidney Int 36 1989 272 279
51. MC Slagman, F Waanders, MH Hemmelder et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial BMJ 343 2011 d4366
52. HJ Lambers Heerspink, FA Holtkamp, HH Parving et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers Kidney Int 82 2012 330 337
53. S Vegter, A Perna, MJ Postma, G Navis, G Remuzzi, P Ruggenenti Sodium intake, ACE inhibition, and progression to ESRD J Am Soc Nephrol 23 2012 165 173
54. CP Wen, JPM Wai, MK Tsai et al. Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study Lancet 378 2011 1244 1253
55. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Kidney Int Suppl 113 2009 S1 130
56. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease Kidney Int Suppl 2 2012 337 414
57. FA Holtkamp, D de Zeeuw, PA de Graeff et al. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy; a post hoc analysis of the combined RENAAL and IDNT trials Eur Heart J 32 2011 1493 1499
58. TH Jafar, CH Schmid, M Landa et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data Ann Intern Med 135 2001 73 87
59. D De Zeeuw, R Parekh, S Soman CKD treatment: time to alter the focus to albuminuria? Adv Chronic Kidney Dis 18 2011 222 223
60. M Tonelli, C Isles, T Craven et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease Circulation 112 2005 171 178
61. C Baigent, MJ Landray, C Reith for the SHARP Investigators The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 2011 2181 2192
62. SC Palmer, JC Craig, SD Navaneethan, M Tonelli, F Pellegrini, GF Strippoli Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis Ann Intern Med 157 2012 263 275
63. SC Palmer, L Di Micco, M Razavian et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis Ann Intern Med 156 2012 445 459
64. KE Chan, JM Lazarus, R Thadhani, RM Hakim Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation J Am Soc Nephrol 20 2009 2223 2233
65. MA Pfeffer, EA Burdmann, CY Chen et al. A trial of darbepoietin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 2009 1 14
66. AK Singh, L Szczech, KL Tang et al. Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 2006 2085 2098
67. D De Zeeuw, R Agarwal, M Amdahl et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial Lancet 376 2010 1543 1551
68. R Thadhani, E Appelbaum, Y Pritchett et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial JAMA 307 2012 674 684
69. K Yamagata, K Ishida, T Sairenchi et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study Kidney Int 71 2007 159 166
70. SI Hallan, SR Orth Smoking is a risk factor in the progression to kidney failure Kidney Int 80 2011 516 523
71. FJ He, GA MacGregor Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials Lancet 378 2011 380 382
72. L Vogt, F Waanders, F Boomsma, D de Zeeuw, G Navis Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan J Am Soc Nephrol 19 2008 999 1007
73. G Eknoyan Obesity and chronic kidney disease Nefrologia 31 2011 397 403
74. M Postorino, C Marino, G Tripepi, C Zoccali for the CREDIT (Calabria Registry of Dialysis and Transplantation) Working Group Abdominal obesity and all-cause and cardiovascular mortality in end-stage renal disease J Am Coll Cardiol 53 2009 1265 1272
75. SD Navaneethan, H Yehnert, F Moustarah, MJ Schreiber, PR Schauer, S Beddhu Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis Clin J Am Soc Nephrol 4 2009 1565 1574
76. D Fouque, M Laville Low protein diets for chronic kidney disease in non diabetic adults Cochrane Database Syst Rev 3 2009 CD001892.
77. B Cianciaruso, A Pota, V Bellizzi et al. Effect of a low- versus moderate-protein diet on progression of CKD: follow-up of a randomized controlled trial Am J Kidney Dis 54 2009 1052 1061
78. N Halbesma, SJL Bakker, DF Jansen et al. High protein intake associates with cardiovascular events but not with loss of renal function J Am Soc Nephrol 20 2009 1797 1804
79. ES Robinson, ND Fisher, JP Forman, GC Curhan Physical activity and albuminuria Am J Epidemiol 171 2010 515 521
80. AG Stack, DA Molony, T Rives, J Tyson, BVR Murthy Association of physical activity with mortality in the US dialysis population Am J Kidney Dis 45 2005 690 701
81. S Heiwe, SH Jacobson Exercise training for adults with chronic kidney disease Cochrane Database Sys Rev 10 2011 CD003236.
82. VL Esnault, A Ekhlas, C Delcroix, MG Moutel, JM Nguyen Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents J Am Soc Nephrol 16 2005 474 481
83. LJ Appel, JT Wright Jr, T Greene for the AASK Collaborative Research Group Intensive blood-pressure control in hypertensive chronic kidney disease N Engl J Med 363 2010 918 929
84. MA Pohl, S Blumenthal, DJ Cordonnier et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations J Am Soc Nephrol 16 2005 3027 3037
85. BE De Galan, V Perkovic, T Ninomiya for the ADVANCE Collaborative Group Lowering blood pressure reduces renal events in type 2 diabetes J Am Soc Nephrol 20 2009 883 892
86. A Patel, S MacMahon, J Chalmers et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2008 2560 2572
87. R Boussageon, T Bejan-Angoulvant, M Saadatian-Elahi et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials BMJ 343 2011 d4169
88. AL Weigert, AI Schafer Uremic bleeding: pathogenesis and therapy Am J Med Sci 316 1998 94 104
89. GM Chertow, GA Block, R Correa-Rotter for the EVOLVE Trial Investigators Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis N Engl J Med 367 2012 2482 2494
90. K Szummer, P Lundman, SH Jacobson for SWEDEHEART Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register J Intern Med 268 2010 40 49
91. P DasMahapatra, SR Srinivasan, J Mokha et al. Subclinical atherosclerotic changes related to chronic kidney disease in asymptomatic black and white young adults: the Bogalusa Heart Study Ann Epidemiol 21 2011 311 317
92. DM Charytan, S Setoguchi, DH Solomon, J Avorn, WC Winkelmayer Clinical presentation of myocardial infarction contributes to lower use of coronary angiography in patients with chronic kidney disease Kidney Int 71 2007 938 945
93. JM Andrade, LHW Gowdak, MCP Giorgi et al. Cardiac MRI for detection of unrecognized myocardial infarction in patients with end-stage renal disease: comparison with ECG and scintigraphy AJR Am J Roentgenol 193 2009 W25 W32
94. Y Iwanaga, S Miyazaki Heart failure, chronic kidney disease, and biomarkers - an integrated viewpoint Circ J 74 2010 1274 1282
95. FS Apple, MM Murakami, LA Pearce, CA Herzog Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease Circulation 106 2002 2941 2945
96. AY Wang, C Wai-Kei Lam The diagnostic utility of cardiac biomarkers in dialysis patients Semin Dial 25 2012 388 396
97. M Seddon, N Curzen Coronary revascularisation in chronic kidney disease. Part II: acute coronary syndromes J Ren Care 36 suppl 1 2010 118 126
98. M Asim, RF Jeffrey Management of acute coronary syndrome in patients with chronic kidney disease: if we don't risk anything, we risk even more Nephron Clin Pract 119 2011 c333 c336
99. AJ Saltzman, GW Stone, BE Claessen et al. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI trial JACC Cardiovasc Interv 4 2011 1011 1019
100. A Abdel-Latif, D Mukherjee, P Mesgarzadeh, KM Ziada Drug-eluting stents in patients with end-stage renal disease: meta-analysis and systematic review of the literature Catheter Cardiovasc Interv 76 2010 942 948
101. G Ashrith, VV Lee, MA Elayda, RM Reul, JM Wilson Short- and long-term outcomes of coronary artery bypass grafting or drug-eluting stent implantation for multivessel coronary artery disease in patients with chronic kidney disease Am J Cardiol 106 2010 348 353
102. U Baber, AS Kini, SK Sharma, MC Kim, ME Farkouh, P Muntner Thrombolysis In myocardial infarction (TIMI) risk score and mortality in patients with advanced chronic kidney disease and on dialysis Am J Cardiol 103 2009 1513 1517
103. CS Fox, P Muntner, AY Chen et al. Use of evidence-based therapies in short-term outcomes on ST-setment elevation muocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network Registry Circulation 121 2010 357 365
104. NI Parikh, SJ Hwang, MG Larson, JB Meigs, D Levy, CS Fox Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control Arch Intern Med 17 2006 1884 1891
105. H Cardinal, F Madore Are cardioprotective drugs underused after a myocardial infarction in patients who suffer from chronic kidney disease? Nephrol Ther 6 2010 162 170
106. PA McCullough, RC Maynard Treatment disparities in acute coronary syndromes, heart failure, and kidney disease Contrib Nephrol 171 2011 68 73
107. HM Krumholz, TE Seeman, SS Merrill et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years JAMA 272 1994 1335 1340
108. AS Levey, PE de Jong, J Coresh et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report Kidney Int 80 2011 17 28
109. FW Asselbergs, GF Diercks, HL Hillege for the PREVEND IT Investigators Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria Circulation 110 2004 2809 2816
110. Heart Outcomes Prevention Evaluation Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy Lancet 355 2000 253 259
111. DC Crews, LE Boulware, RT Gansevoort, BG Jaar Albuminuria: is it time to screen the general population? Adv Chronic Kidney Dis 18 2011 249 257
112. P Gaede, P Vedel, N Larsen, GV Jensen, HH Parving, O Pedersen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 2003 383 393
113. P Gaede, H Lund-Andersen, HH Parving, O Pedersen Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 358 2008 580 591
114. P Ruggenenti, E Perticucci, P Cravedi et al. Role of remission clinics in the longitudinal treatment of CKD J Am Soc Nephrol 19 2008 1213 1224
115. Remission Clinic Task Force and Clinical Research Center "Aldo e Cele Daccò" The Remission Clinic approach to halt the progression of kidney disease J Nephrol 24 2011 274 281